Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Jul;101(1):2–7. doi: 10.1111/j.1365-2249.1995.tb02268.x

Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.

C Richter 1, A Schnabel 1, E Csernok 1, K De Groot 1, E Reinhold-Keller 1, W L Gross 1
PMCID: PMC1553313  PMID: 7621588

Abstract

In this uncontrolled study 15 patients with ANCA-associated systemic vasculitis, who were poor responders to conventional therapy, were treated with single or multiple courses of intravenous immunoglobulin (IVIG), 30 g/day over 5 days. Clinical and serological evaluation was performed before and 4 weeks after IVIG. Six of the 15 patients experienced clinically significant benefit from IVIG. Improvement was confined to single organ manifestations (skin, ENT findings), no improvement was seen with conjunctivitis and scleritis, pericarditis or nephritis. No patient experienced complete remission after IVIG. Repeated courses of IVIG at 4-week intervals were no more effective than single courses. In six anti-proteinase 3 (PR3)-positive patients pretreatment sera were incubated with F(ab')2 fragments of the IVIG preparation in vitro to measure the inhibitory effect of IVIG on anti-PR3 activity. An inhibition of anti-PR3 activity by 25-70% was observed; this did not correlate with clinical effects. Approximately 40% of patients benefited from IVIG treatment, though complete remission of disease activity did not occur. Neither clinical characteristics nor the inhibitory effect of the IVIG preparation on serum anti-PR3 activity in vitro predicted clinical response to this treatment modality.

Full text

PDF
2

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer. 1991 Sep 15;68(6 Suppl):1430–1436. doi: 10.1002/1097-0142(19910915)68:6+<1430::aid-cncr2820681405>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  2. Cherin P., Herson S., Wechsler B., Piette J. C., Bletry O., Coutellier A., Ziza J. M., Godeau P. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991 Aug;91(2):162–168. doi: 10.1016/0002-9343(91)90009-m. [DOI] [PubMed] [Google Scholar]
  3. DeREMEE R. A., McDonald T. J., Harrison E. G., Jr, Coles D. T. Wegener's granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc. 1976 Dec;51(12):777–781. [PubMed] [Google Scholar]
  4. Gross W. L. New developments in the treatment of systemic vasculitis. Curr Opin Rheumatol. 1994 Jan;6(1):11–19. doi: 10.1097/00002281-199401000-00003. [DOI] [PubMed] [Google Scholar]
  5. Gross W. L., Schmitt W. H., Csernok E. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol. 1993 Jan;91(1):1–12. doi: 10.1111/j.1365-2249.1993.tb03345.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gross W. L. Wegener's granulomatosis. New aspects of the disease course, immunodiagnostic procedures, and stage-adapted treatment. Sarcoidosis. 1989 Mar;6(1):15–29. [PubMed] [Google Scholar]
  7. Hoffman G. S., Kerr G. S., Leavitt R. Y., Hallahan C. W., Lebovics R. S., Travis W. D., Rottem M., Fauci A. S. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488–498. doi: 10.7326/0003-4819-116-6-488. [DOI] [PubMed] [Google Scholar]
  8. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schöni M., Vest M., Wagner H. P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981 Jun 6;1(8232):1228–1231. doi: 10.1016/s0140-6736(81)92400-4. [DOI] [PubMed] [Google Scholar]
  9. Jayne D. R., Davies M. J., Fox C. J., Black C. M., Lockwood C. M. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991 May 11;337(8750):1137–1139. doi: 10.1016/0140-6736(91)92797-6. [DOI] [PubMed] [Google Scholar]
  10. Jayne D. R., Esnault V. L., Lockwood C. M. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun. 1993 Apr;6(2):207–219. doi: 10.1006/jaut.1993.1018. [DOI] [PubMed] [Google Scholar]
  11. Jennette J. C., Falk R. J., Andrassy K., Bacon P. A., Churg J., Gross W. L., Hagen E. C., Hoffman G. S., Hunder G. G., Kallenberg C. G. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187–192. doi: 10.1002/art.1780370206. [DOI] [PubMed] [Google Scholar]
  12. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  13. Leavitt R. Y., Fauci A. S., Bloch D. A., Michel B. A., Hunder G. G., Arend W. P., Calabrese L. H., Fries J. F., Lie J. T., Lightfoot R. W., Jr The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990 Aug;33(8):1101–1107. doi: 10.1002/art.1780330807. [DOI] [PubMed] [Google Scholar]
  14. Levine D. S., Fischer S. H., Christie D. L., Haggitt R. C., Ochs H. D. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol. 1992 Jan;87(1):91–100. [PubMed] [Google Scholar]
  15. Liblau R., Gajdos P., Bustarret F. A., el Habib R., Bach J. F., Morel E. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol. 1991 May;11(3):128–131. doi: 10.1007/BF00918680. [DOI] [PubMed] [Google Scholar]
  16. Lüdemann J., Utecht B., Gross W. L. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med. 1990 Jan 1;171(1):357–362. doi: 10.1084/jem.171.1.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Newburger J. W., Takahashi M., Burns J. C., Beiser A. S., Chung K. J., Duffy C. E., Glode M. P., Mason W. H., Reddy V., Sanders S. P. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986 Aug 7;315(6):341–347. doi: 10.1056/NEJM198608073150601. [DOI] [PubMed] [Google Scholar]
  18. Newland A. C., Macey M. G., Veys P. A. Cellular changes during the infusion of high dose intravenous immunoglobulin. Blut. 1989 Jul;59(1):82–87. doi: 10.1007/BF00320254. [DOI] [PubMed] [Google Scholar]
  19. Nölle B., Specks U., Lüdemann J., Rohrbach M. S., DeRemee R. A., Gross W. L. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med. 1989 Jul 1;111(1):28–40. doi: 10.7326/0003-4819-111-1-28. [DOI] [PubMed] [Google Scholar]
  20. Prieur A. M., Adleff A., Debre M., Boulate P., Griscelli C. High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin Exp Rheumatol. 1990 Nov-Dec;8(6):603–608. [PubMed] [Google Scholar]
  21. Reinhold-Keller E., Kekow J., Schnabel A., Schmitt W. H., Heller M., Beigel A., Duncker G., Gross W. L. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 1994 Jun;37(6):919–924. doi: 10.1002/art.1780370622. [DOI] [PubMed] [Google Scholar]
  22. Rossi F., Jayne D. R., Lockwood C. M., Kazatchkine M. D. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol. 1991 Feb;83(2):298–303. doi: 10.1111/j.1365-2249.1991.tb05631.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rostoker G., Desvaux-Belghiti D., Pilatte Y., Petit-Phar M., Philippon C., Deforges L., Terzidis H., Intrator L., André C., Adnot S. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med. 1994 Mar 15;120(6):476–484. doi: 10.7326/0003-4819-120-6-199403150-00005. [DOI] [PubMed] [Google Scholar]
  24. Schmitt W. H., Heesen C., Csernok E., Rautmann A., Gross W. L. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum. 1992 Sep;35(9):1088–1096. doi: 10.1002/art.1780350914. [DOI] [PubMed] [Google Scholar]
  25. Schwartz S. A. Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol. 1990 Mar;10(2):81–89. doi: 10.1007/BF00918189. [DOI] [PubMed] [Google Scholar]
  26. Steppat D., Gross W. L. Stage-adapted treatment of Wegener's granulomatosis. First results of a prospective study. Klin Wochenschr. 1989 Jul 3;67(13):666–671. doi: 10.1007/BF01718027. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES